Enanta Pharmaceuticals, Inc.
ENTA
$13.24
-$0.26-1.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.83% | 42.19% | 46.44% | 35.12% | 19.43% |
| Total Depreciation and Amortization | -2.07% | 0.50% | 38.36% | 168.06% | 103.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 159.00% | -18.28% | -57.86% | -36.87% | -51.04% |
| Change in Net Operating Assets | -92.20% | -102.32% | -2,650.44% | -41.25% | 1,098.59% |
| Cash from Operations | -156.96% | 46.95% | 30.37% | 37.61% | 218.48% |
| Capital Expenditure | 95.48% | 99.41% | 98.36% | 83.71% | 97.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 153.22% | 753.03% | -160.73% | -86.60% | -13,464.47% |
| Cash from Investing | 152.88% | 373.33% | -168.64% | -87.96% | -317.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 79,571.28% | -25.00% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 80.82% | -6.64% | -111.71% | -14.95% | 3.76% |
| Cash from Financing | 13.73% | -5.92% | 1,386.32% | -15.33% | 3.35% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 90.20% | 89.86% | -89.09% | -958.30% | 44.53% |